Northland Securities initiated coverage on shares of Beximco Pharmaceuticals (LON:BXP) in a report issued on Monday. The firm set a “buy” rating and a GBX 75 ($1.04) price target on the stock. Northland Securities’ price target suggests a potential upside of 30.43% from the company’s current price.

Separately, Northland Capital Partners reaffirmed a “corporate” rating on shares of Beximco Pharmaceuticals in a research note on Tuesday, January 30th.

Shares of Beximco Pharmaceuticals (BXP) opened at GBX 57.50 ($0.79) on Monday. Beximco Pharmaceuticals has a one year low of GBX 50.38 ($0.70) and a one year high of GBX 71.75 ($0.99). The company has a market capitalization of $46,180.00 and a P/E ratio of 9.60.

COPYRIGHT VIOLATION WARNING: This article was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at

Beximco Pharmaceuticals Company Profile

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients. It offers allergic disorder, analgesic and antipyretic, anti-infective, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, intravenous fluid, muscloskeletal, oncology, respiratory, skin care, vitamin and mineral supplement, and other products.

Receive News & Ratings for Beximco Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beximco Pharmaceuticals and related companies with's FREE daily email newsletter.